When it comes to the diagnosis and monitoring of neuropathies and sudomotor dysfunctions, healthcare professionals require advanced, reliable, and unique technologies. Out of the few alternatives, SUDOSCAN® stands out.
Holding unique patents, SUDOSCAN® provides a distinct benefit that distinguishes it from the rest of the industry.
Used by doctors, specialists, hospitals, clinics, and pharmacies, SUDOSCAN® confirms its lead in the industry thanks to its singular approach that merges advanced technology with easy testing methods.
Known for being unique, the SUDOSCAN® patents provide exclusive rights, enabling healthcare professionals to access advanced technology for diagnosing and monitoring pathological conditions.
Let’s explore the features that set SUDOSCAN® apart as a unique solution for neuropathy diagnostics and sudomotor dysfunctions.

Redefining Sudomotor Dysfunction Diagnosis with SUDOSCAN®

Expanding the limits of innovative healthcare practices, SUDOSCAN® provides a simple and non-invasive approach for the diagnosis of sudomotor dysfunction, particularly in patients diagnosed with diabetes. This tool is a valuable asset for healthcare professionals, offering reliable and accurate diagnostic capabilities to ensure patient care.

The technology embedded in SUDOSCAN® relies on its own patented technology, designed to give accurate readings using stainless steel electrodes. This leading-edge technology is making a big difference in diagnosing nerve diseases, by simplifying complex procedures and making them more efficient and patient-friendly.

Thanks to its unique features, SUDOSCAN® gained popularity in global healthcare markets, being officially recognized as a reference test in the diagnosis and monitoring of both diabetic neuropathy and other peripheral autonomic neuropathies – typically associated with small fiber neuropathies.

Being a CE marked, Class IIa health regulated product, SUDOSCAN® meets high quality and safety standards. This certification assures healthcare professionals that the device is suitable for regular use while meeting the highest regulatory requirements in the medical field.

Patented Excellence: Unpacking the Exclusive SUDOSCAN® Technology 

SUDOSCAN® is an innovative technology for early detection and tracking of autonomous and small fibre neuropathy. This medical device provides a sudoriparesis stimulation that evaluates small nerve fibres. It is incredibly crucial in managing diabetes complications such as neuropathies to prevent diabetic foot.

SUDOSCAN® holds exclusive patents granted across varying jurisdiction, including the United States and Europe. This highlights the global recognition of its technological and scientific innovation. Each patent demonstrates a unique way and setup to fully assess and monitor sudomotor dysfunctions and neuropathies.

Listed below are the registered patents of SUDOSCAN® :

• “Electrophysiological analysis system and method” (US Patent No. US 8965497B2, European Patent No. EP 1898783B1),
• “Electrophysiological analysis system” (US Patent No. US 8655443B2, European Patent No. EP 2124736B1),
• “Assessment of sudomotor function for peripheral diabetic neuropathy evaluation” (US Patent No. US 8934954B2),
• “Device for measuring electrophysiological data with improved reliability” (US Patent No. US 10537272B2),
• “Electrodes” (US Designs No. D815746 and D796681, European Designs No. EU0028464100001S and EU0028464100002S)

The patent titled “Electrophysiological analysis system and method” (US Patent No. US 8965497B2, European Patent No. EP 1898783B1) demonstrates SUDOSCAN’s revolutionary approach to electrophysiological analysis, giving healthcare professionals a new way to accurately and non-invasively diagnose and monitor neuropathies.

The patent titled “Electrophysiological analysis system” (US Patent No. US 8655443B2, European Patent No. EP 2124736B1) signifies the robust system design of SUDOSCAN® that ensures reliable and reproducible results, enhancing the confidence of healthcare professionals in delivering diagnostic outcomes and patient management.

The patent titled “Assessment of sudomotor function for peripheral diabetic neuropathy evaluation” (US Patent No. US 8934954B2) underscores the unique capability of SUDOSCAN® in recognizing not just neuropathies but specifically diabetic neuropathy. This patent precisely captures the potential of SUDOSCAN® in limiting diabetes complications, turning to be a significant asset for healthcare providers handling diabetic patients.

The patent titled “Device for measuring electrophysiological data with improved reliability” (US Patent No. US 10537272B2) reflects the commitment of SUDOSCAN® in ensuring consistent and reliable data generation, solidifying its foothold as a premier healthcare technology on the market.

Finally, the designs related to “Electrodes” (US Designs No. D815746 and D796681, European Designs No. EU0028464100001S and EU0028464100002S) highlight the unique electrode design of SUDOSCAN®’s electrodes. This brings out the device’s overall performance and easy use, while making sure it’s safe and effective.

By including all these patented innovations, SUDOSCAN® stands out as an indispensable tool for healthcare professionals globally in managing a multitude of neuropathies, including the hard-hitting repercussions of diabetes.

SUDOSCAN® Vs. Competition: The Differentiating Factor in Sudomotor Dysfunction Diagnosis

In today’s changing healthcare landscape, SUDOSCAN® is a step forward, making a big difference in the diagnosis and monitoring of neuropathies and sudomotor dysfunctions.

Compared to other solutions, our method is ahead with its innovative approach.

• Our solution is simple and non-invasive. Unlike many other testing methods, patient comfort and convenience are at the forefront of our test design.
• The SUDOSCAN® method uses stainless steel electrodes to assess sudomotor function, avoiding the discomfort and potential complications associated with invasive procedures.
• The ease of this method improves patient compliance, leading to more robust and reliable results.
• What further distinguishes SUDOSCAN®  is the high prevalence of sudomotor dysfunction detection in diabetic patients, a conclusion made evident in a study conducted in Romania.
• Additionally, SUDOSCAN® has built a strong international presence, becoming a reference test in many countries. This highlights our global relevance and applicability.
• The SUDOSCAN CAN risk score positively correlates with various factors including hand ESC, DBP, levels of glycated hemoglobin, TCNS, NDS, and NSS. This data-driven approach helps healthcare professionals provide targeted treatment, enhancing patient outcomes.

SUDOSCAN® represents a significant advancement in the diagnosis and monitoring of neuropathies. Its exclusive patented technology is more than a competitive advantage—it’s a lifeline for countless patients worldwide.